The icobrain portfolio offers cloud-based AI solutions to assist healthcare professionals in adopting clinical practice guidelines.1-3
icobrain is an image analysis service to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT.
The icobrain output consists of concise disease-specific reports with normative reference values and color-coded segmentations in DICOM format to help the radiologist and neurologist interpret and communicate the patient’s condition for patients with neurological diseases.
An additional output is the Prepopulated Reporting Template (PRT), translating the volumes and population statistics into natural language. The PRT can be easily copied into and edited in the radiological report.
The icobrain portfolio is FDA cleared and CE marked for clinical usage.
Explore the icobrain portfolio
A cloud-based AI solution to quantify disease-specific brain structures on MR and CT.
Contact us for more information
icobrain is a medical device intended for use by healthcare professionals only.
- icobrain mr is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images.
- Icobrain ct is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of non-contrast computed tomography (NCCT) images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on NCCT images.
For complete information about precautions and optimal usage conditions, we recommend consulting the instructions for use supplied with the software or by your local Guerbet representative(s). For use only in countries with applicable health authority registrations.
Class Im/CE SGS Belgium 1639/FDA cleared